Androgen replacement therapy in aging men

Nurse Practitioner

Volumn 29, Issue 10, 2004, Pages 58-64

  Katz, Anne ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; TESTOSTERONE;

AGED; AGING; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; MALE; PROSTATE TUMOR; REVIEW;

AGED; AGING; ANDROGENS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 16544362775     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1097/00006205-200410000-00008     Document Type: Article

References (44)

1. Vermeulen A: Andropause. Maturitas 2000;34(1):5-15.
2. Basaria S, Dobs A: Risks versus benefits of testosterone therapy in elderly men. Drugs Aging 1999;15(2):131-42.
3. Morales A: The andropause: bare facts for urologists. BJU Int 2003; 91(4):311-3.
4. Heaton J, Morales A: Andropause - a multisystem disease. Can J Urol 2001;8 (2):1213-22.
5. Morales A: Testosterone replacement: when is there a role? Int J Impot Res 2000;12 (Suppl 4):S112-S118.
6. Novak A, Brod M, Elbers J: Andropause and quality of life: findings from patient focus groups and clinical experts. Maturitas 2002;43(4):231-7.
7. Juul A, Skakkebaek N: Androgens and the aging male. Human Reprod Update 2002;8(5):423-33.
8. Hoffman A: Should we treat the andropause? Am J Med 2001;111(4):322-3.
9. Oudshoorn N: Menopause only for women? The social construction of menopause as an exclusively female condition. J Psychom Obstet Gynaecol 1997;18:137-44.
10. Schutheiss D, Jonas U, Musitelli S: Some historical reflections on the ageing male. World J Urol 2002;20(1):40-4.
11. Wyllie M: ADAM and the andropause. BJU International 2003;91(9):883-4.
12. Gould D, Petty R, Jacobs H: For and against: the male menopause-does it exist? Brit Med J 2000;320(7238):858-61.
13. Tan R, Philip P: Perceptions of and risk factors for andropause. Arch Androl 1999;43(2):97-103.
14. IMS Health Inc: IMS sales data 2001. Westport, Conn.
15. Burns-Cox N, Gingell C: The andropause: fact or fiction? Postgrad Med J 1997;73(863):553-6.
16. Morales A, Lunenfeld B: Investigation, treatment and monitoring of late-onset hypogonadism in males: official recommendations of ISSAM. Aging Male 2002;5(2):74-86.
17. Flynn V, Hellstrom W: Androgen deficiency in the aging male: pathophysiology, diagnosis, and treatment alternatives. Curr Urol Rep 2002;2(6):473-9.
18. Wheeler M: The determination of bioavailable testosterone. Annals of Clinical Biochemistry 1995;32(Part 4 July):345-57.
19. Morales A, Tenover J: Androgen deficiency in the aging male: when, who and how to investigate and treat. Urologic Clinics of North America 2002;29(4):975-82.
20. Bain J: Andropause: testosterone replacement therapy for aging men. Canadian Family Physician 2001;47(1):91-7.
21. Peate I: The male menopause: possible causes, symptoms and treatment. British Journal of Nursing 2003;12(2):80-4.
22. Howell S, Shalet S: Testosterone deficiency and replacement. Hormone Research 2001;56(Suppl 1):86-92.
23. Yialamas M, Hayes F: Androgens and the aging male and female. Best Practice & Research Clinical Endocrinology and Metabolism 2003;17(2):223-36.
24. Haren M, Morley J, Chapman I, et al.: Defining ‘relative’ androgen deficiency in aging men: how should testosterone be measured and what are the relationships between androgen levels and physical, sexual and emotional health? Climacteric 2002;5(1):15-25.
25. Haren M, Morley J, Chapman I, et al.: Defining ‘relative’ androgen deficiency in aging men: how should testosterone be measured and what are the relationships between androgen levels and physical, sexual and emotional health? Climacteric 2002;5(1):15-25.
26. Tenover J: Testosterone replacement therapy in older adult men. International Journal of Andrology 1999;22(5):300-6.
27. Partin A, Hanks G, Klein E, et al.: Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology 2002;16(8):1024-47.
28. Rolf C, Nieschlag E: Potential adverse effects of long-term testosterone therapy. Bailliere’s Clinical Endocrinology and Metabolism 1998;12(3):521-34.
29. Gooren L: Androgen deficiency in the aging male: benefits and risks of androgen supplementation. Journal of Steroid and Molecular Biology 2003; 85(2):349-55.
30. Slater S, Oliver R: Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs & Aging 2000;17(6):431-9.
31. Guay A, Perez J, Fitaihi W, et al.: Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer. Endocrine Practice 2000;6(2):132-8.
32. Morales A:Androgen replacement therapy and prostate safety. European Urology 2002;41(2):113-20.
33. Hajjar R, Kaiser F, Morley J: Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. Journal of Clinical Endocrinology and Metabolism 1997; 82(11):3793-6.
34. Snyder P, Peachey H, Berlin J, et al.: Effects of testosterone replacement in hypogonadal men. Journal of Clinical Endocrinology and Metabolism 2000;85(8):2670-7.
35. Pechersky A, Mazurow V, Semiglazov V, et al.: Androgen administration in middle-aged and aging men: effects of oral testosterone undecanoate on di-hydrotestosterone, oestradiol and prostate volume. International Journal of Andrology 2002;25(2):119-25.
36. Gertstenbluth R, Maniam P, Corty E, et al.: Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. Journal of Andrology 2002;23(6):922-6.
37. Sih B, Morley J, Kaiser F, et al.: Testosterone replacement in older men hypogonadal men: a 12-month randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 1997;82(6):1661-7.
38. Svete, D, Canby E, Thompson I, et al.: The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfuncion. The Journal of Urology 1997;158(5):1775-7.
39. Kenny A, Prestwood K, Raisz L: Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with low testosterone levels. Endocrine Research 2000;26(2):153-68.
40. Morales A, Bain J, Ruijs A, et al.: Clinical practice guidelines for screening and monitoring male patients receiving testosterone supplementation therapy. International Journal of Impotence Research 1996;8(2):95-7.
41. Janssens H, Vanderschuereb D: Endocrinological aspects of aging in men: is hormone replacement of benefit? European Journal of Obstetrics & Gynecology and Reproductive Biology 2000;92(1):7-12.
42. Rhoden E, Morgentaler A: Risks of testosterone-replacement therapy and recommendations for monitoring. The New England Journal of Medicine 2004;350(5):482-92.
43. Bhasin S, Singh A, Phong Mac R, et al.: Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. Journal of Andrology 2003;24(3):299-311.
44. Tan R, Culberson J: An integrative review on current evidence of testosterone replacement therapy for the andropause. Maturitas 2003;45(1):15-27.